Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection

Blood

Volumn 92, Issue 12, 1998, Pages 4581-4590

  Hale, Geoff ^a   Zhang, Mei Jie ^b   Bunjes, Donald ^b   Grant Prentice, H ^b   Spence, David ^b   Horowitz, Mary M ^b   John Barrett, A ^b   Waldmann, Herman ^b  

^a Therapeutic Antibody Centre   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD52 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CAMPATH 1G; MONOCLONAL ANTIBODY CAMPATH 1M; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0032535279     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.12.4581     Document Type: Article

References (16)

1. Gluckman E: Immunosuppressive drugs for the prevention of acute graft-vs-host disease, in Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds): Graft-vs-Host Disease Immunology, Pathophysiology and Treatment. New York, NY, Marcel Dekker, 1990, p 389
2. Atkinson K: Treatment of extensive human chronic graft-vs-host disease, in Burakoff SJ, Deeg HJ, Ferrara J, Atkinson K (eds): Graft-vs-Host Disease Immunology, Pathophysiology and Treatment. New York, NY, Marcel Dekker, 1990, p 681
3. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Dupont B, Good RA, O'Reilly RJ: Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet 2:327, 1981
4. Prentice HG, Blacklock HA, Janossy G, Bradstock KF, Skeggs D, Goldstein G. Hoffbrand AV: Use of anti-T cell monoclonal antibody OKT3 to prevent acute graft versus host disease in allogeneic bone marrow transplantation for acute leukemia. Lancet 1:700, 1982
5. Prentice HG, Janossy G, Price-Jones L, Trejdosiewicz LK, Panjwani D, Graphakos S, Ivory K, Blacklock HA, Gilmore MJML, Tidman N, Skeggs DBL, Bail S, Patterson J, Hoffbrand AV: Depletion of T lymphocytes in donor marrow prevents significant graft-versushost disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 1:472, 1984
6. Waldmann H, Or R, Hale G, Weiss L, Cividalli G, Samuel S, Manor D, Brautbar C, Polliack A, Rachmilewitz EA, Slavin S: Elimination of graft versus host disease by in vitro depletion of alloreactive lymphocytes using a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 2:483, 1984
7. Noga SJ, Donnenberg AP, Schwartz CL, Strauss LC, Civin CI, Santos GW: Development of a simplified centrifugation elutriation procedure for depletion of lymphocytes from human bone marrow. Transplantation 41:214, 1986
8. Filipovitch AH, Vallera DA, Youle RJ, Haake R, Blazar BR, Arthur D, Neville Ramsay NK, McGlave P, Kersey JH: Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow. Transplantation 44:62, 1987
9. Hale G: Campath-1 Antigen (CD52), in Delves PJ, Roitt I (eds) Encyclopedia of Immunology London, UK, Academic, 1998, p 402
10. Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, Waldmann H: Removal of T cells from bone marrow for transplantation: A monoclonal antilymphocyte antibody that fixes human complement. Blood 62:873, 1983
11. Heit W, Bunjes D, Weisneth M, Schmeiser T, Arnold R, Hale G, Waldmann H, Heimpel H: Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute GvHD in allogeneic bone marrow transplantation. Br J Haematol 64:479, 1986
12. Hale G, Cobbold S, Waldmann H: T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation 45:753, 1988
13. Hale G, Waldmann H, for CAMPATH users: Control of graftversus-host disease and graft rejection by T cell depletion of donor and recipient with CAMPATH-1 antibodies. Results of matched sibling transplants for malignant diseases. Bone Marrow Transplantation 13:597, 1994
14. Hale G, Waldmann H, for CAMPATH users: CAMPATH-1 monoclonal antibodies in bone marrow transplantation. Hematotherapy 3:15, 1994
15. Bunjes D, Heit W, Arnold R, Schmeiser T, Wiesneth M, Carbonell F, Porzsolt F, Raghavachar A, Heimpel H: Evidence for the involvement of host-derived OKT8-positive T cells in the rejection of T-depleted HLA-identical bone marrow grafts. Transplantation 43:501, 1987
16. Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ: Graft rejection in recipients of T-cell depleted HLA-identical marrow transplants for leukemia. Identification of host-derived anti-donor allocytotoxicT lymphocytes. Transplantation 43:842, 1987